Sandoz Group Ltd

SDZ

Equity

ISIN CH1243598427 / Valor 124359842

SIX Swiss Exchange (2024-11-21)

CHF 39.65-0.55%

Sandoz Group Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sandoz Group Ltd is a global pharmaceutical company that offers a wide range of biosimilar and generic medicines, providing over 800 million patient treatments annually. With a portfolio of approximately 1,500 quality products, the company plays a significant role in improving healthcare by generating substantial cost savings in the US and Europe, ultimately resulting in a total social impact estimated at around USD 400 billion per year worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales

In the fourth quarter of 2023, Sandoz Group Ltd reported net sales of USD 9.6 billion, reflecting a 7% increase in constant currencies compared to the previous year. This growth was driven by strong demand, product launches, and continued performance of key products like Omnitrope® and Hyrimoz®.

Core EBITDA

Sandoz Group Ltd's core EBITDA for Q4 2023 was USD 1.7 billion, down from USD 1.9 billion in the prior year. The core EBITDA margin decreased to 18.1% from 21.3% in 2022, impacted by higher input costs, investments in sales and marketing, and standalone costs post-separation.

Net Income

For the fourth quarter of 2023, Sandoz Group Ltd reported a net income of USD 80 million, a significant decrease from USD 850 million in the previous year. This decline was primarily due to higher legal and separation costs, as well as increased input costs.

Free Cash Flow

Sandoz Group Ltd's free cash flow for Q4 2023 was negative USD 0.2 billion, compared to a positive USD 0.8 billion in the prior year. The decrease was mainly due to lower cash flow from operating activities and higher capital expenditures.

Net Debt

As of the end of Q4 2023, Sandoz Group Ltd's net debt stood at USD 3.1 billion, up from USD 3.0 billion in the previous year. The increase in net debt was attributed to financing activities related to the company's separation and spin-off from its former parent.

Summarized from source with an LLMView Source

Key figures

50.8%1Y

%3Y

%5Y

Performance

29.0%1Y

30.0%3Y

30.0%5Y

Volatility